Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama sheds light on the pharmaceuticals industry behind them ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

Lilly is a little vague on when it will now file donanemab with the FDA – suggesting on its fourth quarter 2021 results call that it may do so later this year – but reiterated that it has ...